The principles and the main results of cancer vaccine strategies so far implemented for the treatment of patients with colorectal carcinoma are summarized and the most recent preclinical tumor immunology insights that might change the way to design the next generation of cancer vaccines are discussed.
This review aims to discuss current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines.
Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al.· 1 citation
BACKGROUND
With the rapid advancements in oncology, immunology, and molecular biology, immunotherapy has emerged as a cornerstone of anti-tumor treatment, complementing traditional modalities such as surgery, radiotherapy, and chemotherapy. Therapeutic cancer vaccines are a promising immunotherapy strategy that deliver...
Ju-Wei Gao, Yue Sun, Zi-Jing Han et al.· Immunological Investigations· 0 citations
Current and emerging treatment approaches based on modulation of the immune response, with particular emphasis on immune checkpoint inhibitors, targeted therapies, and mRNA vaccines are discussed.
Artur Marcysiak, Patrycja Mularczyk, Nina Polek et al.· International Journal of Inn...· 0 citations
This review focuses on major vaccine platforms and proposes a comparative framework for understanding therapeutic melanoma vaccine development and immunologic rationale, and synthesizes contemporary clinical trial activity and immunologic principles to inform future research.
Michael Y. Bian, Reagan Stevens, Ankit Mangla et al.· Vaccines· 0 citations
Simple Summary Immunotherapy has become an important treatment strategy for patients with advanced melanoma. Melanoma antigen recognized by T cells 1 (MART-1) has been extensively investigated as a target for a variety of immunotherapeutic approaches, including DNA- and peptide-based vaccines, adoptive cell therapies,...
A. Alshevskaya, Sofya Tsarikova, E. Golikova et al.· Cancers· 0 citations
The rationale for targeting established and emerging antigens in non-small cell and small cell lung cancer, including HER2, TROP2, c-MET, HER3, CEACAM5, DLL3, and other promising targets currently under clinical investigation are discussed.
P. Paliogiannis, G. Fara, A. Zinellu et al.· Current Issues in Molecular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
